Table 1.
Participant Baseline Characteristics (Base Study)
| rVSVΔG-ZEBOV-GP | |||||
|---|---|---|---|---|---|
| Lot Aa | Lot Ba | Lot Ca | High Doseb | Placebo | |
| Participants in population, n | 266 | 265 | 267 | 266 | 133 |
| Female sex, n (%) | 143 (53.8) | 135 (50.9) | 138 (51.7) | 149 (56.0) | 72 (54.1) |
| Age, y, mean (SD) | 41.3 (13.4) | 41.5 (12.4) | 40.9 (13.1) | 41.7 (13.4) | 41.1 (13.7) |
| Race, n (%) | |||||
| American Indian or Alaska Native | 2 (0.8) | 2 (0.8) | 0 (0.0) | 0 (0.0) | 1 (0.8) |
| Asian | 0 (0.0) | 1 (0.4) | 3 (1.1) | 2 (0.8) | 3 (2.3) |
| Black | 78 (29.3) | 70 (26.4) | 82 (30.7) | 83 (31.2) | 37 (27.8) |
| Multiple | 3 (1.1) | 4 (1.5) | 7 (2.6) | 2 (0.8) | 1 (0.8) |
| Pacific Islander | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.8) | 1 (0.8) |
| White | 183 (68.8) | 188 (70.9) | 175 (65.5) | 177 (66.5) | 90 (67.7) |
| BMI, kg/m2, mean (SD)c | 30 (8) | 29 (7) | 31 (8) | 29 (7) | 30 (7) |
Abbreviations: BMI, body mass index; pfu, plaque-forming units; rVSVΔG-ZEBOV-GP, recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine. (used with permission from Oxford University Press [23]).
a Lots A, B, C = nominal 2 × 107 pfu.
b High-dose = nominal 1 × 108 pfu.
c Participants with data: Lot A, n = 263; Lot B, n = 264; Lot C, n = 265; high-dose, n = 264; placebo, n = 133.